Substance / Medication

Proguanil hydrochloride

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Bullous erythema multiforme after treatment with Malarone, a combination antimalarial composed of atovaquone and proguanil hydrochloride.
Remich Shon A, Otieno Walter, Polhemus Mark E et al. · Trop Doct · 2008
PMID: 18628561Case Report
Quinine-resistant severe falciparum malaria effectively treated with atovaquone and proguanil hydrochloride combination therapy.
Uchiyama Hitoji, Okamoto Akio, Sato Katsuaki et al. · Intern Med · 2004
PMID: 15335195Case Report
Evidence of Plasmodium falciparum malaria resistant to atovaquone and proguanil hydrochloride: case reports.
Färnert Anna, Lindberg Johan, Gil Pedro et al. · BMJ · 2003
PMID: 12649236Case ReportFull text (PMC)
Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride.
Plöger Gerlinde F, Abrahamsson Bertil, Cristofoletti Rodrigo et al. · J Pharm Sci · 2018
PMID: 29571740Review
Treatment of avian malaria in captive African penguins () by the combination of atovaquone and proguanil hydrochloride.
Samarelli Rossella, Pugliese Nicola, Saleh Medhat et al. · Int J Vet Sci Med · 2025
PMID: 40007641OtherFull text (PMC)
In vitro effect of the antimalarial drug proguanil hydrochloride on viability and DNA damage in human peripheral blood lymphocytes.
Gajski Goran, Dinter Domagoj, Garaj-Vrhovac Vera · Environ Toxicol Pharmacol · 2010
PMID: 21787658Other
Atovaquone and proguanil hydrochloride.
Am J Health Syst Pharm · 2000
PMID: 11127694Other
Histopathological and ultrastructural assessment of atovaquone-proguanil hydrochloride combination in chronic murine toxoplasmosis.
Elmehankar Manar S, Elhenawy Abeer A, Aboukamar Wafaa A et al. · Ultrastruct Pathol · 2021
PMID: 34595988Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Proguanil hydrochloride (substance)
SNOMED CT
395845004
UMLS CUI
C0546856

Clinical Data

This intervention maps to 1 entities in the Healos knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.